MedTrace Logo

A First Time in Human Study of GSK586529 in Healthy Volunteers

NCT00703547 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-08-22

No results posted yet for this study

Summary

A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male subjects. Subjects will be divided into two cohorts with alternate panel design. The study is investigating the safety, tolerability and pharmacokinetics of single oral escalating doses of GSK586529.

Conditions

  • Depressive Disorder and Anxiety Disorders

Interventions

DRUG

GSK586529 capsules

GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.

DRUG

GSK586529 tablets

GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.

DRUG

Placebo

Placebo tablets and capsules will be provided to subjects.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-28
Primary Completion
2008-04-11
Completion
2008-04-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703547 on ClinicalTrials.gov